Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oscar Health, Inc. (NYSE: OSCR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Oscar identifies itself in these filings as a healthcare technology company whose Class A common stock trades on the New York Stock Exchange under the symbol OSCR. Through its reports, investors can review how the company structures its health insurance operations, technology initiatives, and capital markets activities.
Oscar’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide overviews of its Individual & Family health plans, health technology solutions under the +Oscar brand, risk factors, and detailed financial statements. These core filings typically include information on revenues, medical costs, selling, general, and administrative expenses, membership metrics, and key non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business drivers.
The company’s current reports on Form 8-K offer more targeted updates. Recent 8-K filings describe quarterly financial results, reaffirmed guidance, and capital structure actions such as the issuance of 2.25% Convertible Senior Subordinated Notes due 2030, related capped call transactions, and an exchange agreement involving 7.25% Convertible Senior Notes due 2031. Other 8-Ks detail amendments to investment agreements, the planned termination of a revolving credit facility in connection with a notes offering, and changes to executive employment agreements and compensation structures.
Investors can also use this page to access information on convertible debt terms, events of default, subordination provisions, and potential share dilution from note conversion, all of which are described in Oscar’s indentures and related exhibits. Stock Titan’s AI summaries help explain the implications of these filings, highlight key sections of lengthy documents, and surface important items such as changes in guidance, financing transactions, and governance-related disclosures. This makes it easier to understand how Oscar’s regulatory filings relate to its health insurance operations, technology platform, and long-term financial strategy.
Oscar Health, Inc. reported an insider stock sale by a person who is both a director and the company’s President of Technology & CTO. On 12/24/2025, this insider sold 38,835 shares of Class A common stock in an open-market transaction. The sale is coded as a disposition and left the insider with 438,348 shares beneficially owned directly.
The shares were sold at a weighted average price of $15.00 per share, with individual trades executed in a narrow range between $15.00 and $15.01. The filing notes that the transaction was carried out under a Rule 10b5‑1 trading plan that had been adopted on September 23, 2025, indicating it was pre-arranged rather than an ad hoc sale.
Oscar Health, Inc. disclosed that it entered into an amended and restated employment agreement with Mark T. Bertolini effective December 22, 2025. The new agreement runs through April 1, 2029, providing a multi-year commitment, and then automatically renews for additional one-year periods unless either party decides not to extend it. The company also notes that, apart from specified 2026 long-term incentive awards, Mr. Bertolini is not expected to receive additional long-term incentive or equity-based awards before calendar year 2029.
A shareholder has filed a notice under Rule 144 to sell 57,300 shares of common stock through Morgan Stanley Smith Barney LLC on or about 12/24/2025 on the NYSE, with an indicated aggregate market value of $850,332.00. The filing notes that 229,010,000 shares of this class were outstanding at the time of the notice.
The seller, identified as Mario Schlosser, acquired these 57,300 shares in an open market purchase for cash on 09/16/2021. Over the past three months, the same shareholder has reported additional sales of common shares, including 23,965 shares on 12/02/2025 for $397,579.35, 105,300 shares on 11/12/2025 for $1,584,765.00, and 286,182 shares on 11/11/2025 for $4,369,999.14.
Oscar Health, Inc. officer reports small share sale under 10b5‑1 plan. The company’s Chief Legal Officer reported selling 1,852 shares of Class A common stock on 12/02/2025 at a weighted average price of $16.59 per share. The transaction was coded as a sale and was executed under a pre-arranged Rule 10b5-1 instruction letter entered into on August 8, 2025 to cover tax withholding obligations from vesting equity awards. After this sale, the officer beneficially owns 179,241 shares of Oscar Health, Inc. common stock directly.
Oscar Health, Inc. reported an insider stock transaction by a director and its President of Technology & CTO. On 12/02/2025, the executive sold 23,965 shares of Class A common stock in an open-market transaction coded as a sale at a weighted average price of $16.59 per share. Following this transaction, the executive directly owned 477,183 shares of Class A common stock.
The company notes that the sale was made under a Rule 10b5-1 instruction letter entered into on August 8, 2025, and was intended to satisfy the reporting person's tax withholding obligations arising from the vesting of previously granted equity awards. The reported sale occurred through multiple trades at prices ranging from $16.37 to $16.78 per share.
Oscar Health, Inc. reported an insider stock sale by a senior officer. On 12/02/2025, the President of Oscar Insurance sold 7,338 shares of Class A common stock at a weighted average price of $16.59 per share. After this transaction, the reporting person beneficially owns 172,527 shares directly.
The sale was made under a pre-arranged Rule 10b5-1 trading instruction entered into on August 8, 2025 and was intended to cover the officer’s tax withholding obligations related to the vesting of previously granted equity awards. The shares were sold in multiple trades at prices ranging from $16.37 to $16.78.
Oscar Health, Inc. reported that its Chief Financial Officer sold 25,135 shares of Class A common stock on 12/02/2025 at a weighted average price of $16.59 per share. The sale was made under a pre-arranged Rule 10b5-1 instruction letter entered into on August 8, 2025, to cover the executive’s tax withholding obligations related to the vesting of previously granted equity awards.
Following this transaction, the CFO beneficially owns 1,351,034 shares of Oscar Health Class A common stock, held directly.
Oscar Health, Inc. (OSCR) reported an insider stock sale by its Chief Accounting Officer. On 12/02/2025, the officer sold 4,149 shares of Class A common stock in an open-market transaction coded as a sale. The weighted average price was $16.59 per share, with individual trades occurring between $16.37 and $16.78.
After this transaction, the officer beneficially owned 203,450 shares of Oscar Health Class A common stock. The sale was carried out under a Rule 10b5-1 instruction letter dated August 8, 2025, and was intended to satisfy tax withholding obligations upon the vesting of previously granted equity awards.
OSCR filed a notice of proposed sale covering 28,737 shares of its Class A Common Stock, to be sold through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $480,770.01. The approximate sale date indicated is 12/02/2025.
The shares relate to 54,849 shares of Class A Common Stock acquired on 12/01/2025 through vesting of restricted stock units under a registered plan in exchange for services rendered. The filing notes that 229,010,000 shares of this class were outstanding, providing context for the size of the planned sale.
Oscar Health (OSCR) filed a notice of proposed insider share sales under Rule 144. The filing covers a planned sale of 8,398 shares of Class A common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $140,498.54 at the time of the notice. The issuer had 229,010,000 shares of Class A common stock outstanding.
The securities to be sold were acquired on 12/01/2025 as restricted stock units vesting under a registered plan, in consideration for services rendered, with 14,168 shares acquired on that date. The person for whose account the securities are to be sold represents that they are not aware of any material adverse, non‑public information about Oscar Health’s current or prospective operations.
FAQ
What is the current stock price of Oscar Health (OSCR)?
What is the market cap of Oscar Health (OSCR)?
